|
The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: ---------- Arecor Therapeutics PLC - Cambridgeshire, England-based biopharmaceutical company - Announces that it has concluded a positive Type C meeting with the US Food & Drug Administration for AT278 in people with both type 1 and type 2 diabetes with high daily insulin needs. Explains the purpose of the meeting was to discuss the design of a proposed phase 2 clinical study for AT278, ahead of a planned Investigational New Drug submission. Positive FDA feedback and guidance on the clinical trial design is a major achievement for Arecor and a significant step toward a successful phase 2 study, company says. AT278 is Arecor’s proprietary formulation of an ultra-concentrated and ultra-rapid acting insulin. Arecor plans to submit the phase 2 IND to the FDA during 2026 with the aim of commencing enrolment for the phase 2 study later in that year. The proposed study will be conducted in the US. The study will build upon the positive phase 1 data already generated on AT278 in both type 1 and type 2 diabetes where it demonstrated superiority to existing insulin products, NovoRapid and Humulin R U-500. ---------- Tap Global Group PLC - London-based provider of app-based cryptocurrency payment and settlement services - Announces it has entered into a strategic partnership with tell.money to integrate its open banking gateway into the Tap Group platform. Open banking is a framework that allows consumers to securely share financial data with third-party providers through standardised APIs, with their consent. This development is a cornerstone of Tap Group’s strategy to build a fully regulated bridge between traditional finance and blockchain technology, company says. ‘This is a fundamental building block that strengthens our platform and provides the launchpad for future product innovation, moving us decisively closer to offering a complete, all-in-one financial solution,’ says Chief Executive Arsen Torosian. ---------- Thor Energy PLC - US and Australia-focused mineral exploration company - Announces the signing of a term sheet with DISA Technologies Inc to seek to evaluate and if successful, treat historically abandoned uranium mine waste dumps and recover saleable uranium and other critical minerals concentrates at Thor’s Colorado uranium claims. Thor holds 25% ownership rights to uranium minerals on US Bureau of Land Management territory via its US subsidiary Standard Minerals Inc that holds the projects in Colorado, along with the 75% holder, London-listed Metals One PLC. Says Standard is to be paid a gross revenue share of any saleable uranium and other critical mineral concentrates recovered. No capital expenditure or operating expenditure is payable by Standard or Thor. Thirteen separate prospective waste dumps have been ground surveyed at Standard’s Colorado projects; others may be added to this inventory over time. Metals One Chair Craig Moulton comments: ‘We are delighted to have executed this Term Sheet with DISA, which creates a pathway for Metals One to potentially generate revenue from our U.S. uranium portfolio.’ ---------- Gem Resources PLC - operator of Gravelotte, an emerald mine in South Africa - Raises £2.1 million before expenses through a £617,320 subscription from newly appointed Executive Chair Louis Ching, and the issuance of £1.5 million in unsecured convertible loan notes. Ching is appointed to the board as of Thursday with immediate effect, and currently also serves as chair & managing director of PT International Development Corp Ltd. Funds raised will be used to strengthen the company’s cash position, and progress exploration and development at Gravelotte, and at the Curlew emerald mine in Australia. ‘I believe GEMR has enormous potential,’ says Ching. ‘The company has good assets but has historically been underfunded. I look forward to working with the board to unlock this potential and to build long-term value for all shareholders.’ ---------- capAI PLC - company focused on artificial intelligence systems for media and medicine - Receives notices of exercise of warrants to subscribe for a total of 102.1 million shares. The total consideration paid is £70,162.50. ---------- Afentra PLC - upstream operator in Africa with carried interest in Odewayne block onshore in southwestern Somaliland - Announces that it has signed heads of terms with Angola’s National Agency of Petroleum, Gas and Biofuels for the Risk Service Contract for offshore Block 3/24, located adjacent to its existing Block 3/05 & 5A interests in Angola. The formal award of the license is expected in the coming months following the completion of the government approval process. This increases Afentra’s gross offshore acreage position to 810 kilometres squared from 265km2. Given its proximity to Block 3/05 it offers low-cost development potential. ‘This will provide upside potential to enhance the overall redevelopment plan for the Block 3/05 area where we expect to significantly increase production and reserves, delivering long-term value and cashflows. Furthermore, we see potential for future infrastructure led exploration given the prospectivity of the area,’ says Chief Executive Paul McDade. ---------- Syncona Ltd - London-based investor in life science companies - Portfolio company Beacon Therapeutics announces new results from two phase 2 trials, Skyline and Dawn, evaluating the company’s lead programme, laru-zova, in patients with X-linked retinitis pigmentosa. The data demonstrates that laru-zova was generally well-tolerated by Skyline participants through month 36 and Dawn participants at 9 months or beyond and showed sustained improvements across several key measures of visual function, including low luminance visual acuity and microperimetry. The results were presented at the Euretina 2025 Conference being held in Paris. Beacon is also evaluating low luminance visual acuity as the primary endpoint in its ongoing pivotal Vista trial of laru-zova for the treatment of XLRP. Beacon recently completed enrolment of this trial and expects to report topline data in the second half of calendar year 2026, which the Syncona Investment Management Ltd team view as a potential key value inflection point for the company. ---------- Savannah Resources PLC - lithium development company - Provides an update on a number of ongoing workstreams at the Barroso Lithium Project in Portugal and the project’s development schedule. Savannah continues to make progress towards its goal of developing the project into a key asset in Europe’s lithium battery value chain. Says the resource element of the current drilling programme was completed in July with a total of 12,463 metres drilled across 103 holes. Says work is well advanced on new JORC resource estimates for the Grandao, Pinheiro and Reservatorio orebodies which Savannah expects to publish later in September. Tonnage increases are expected at the Reservatorio and Pinheiro orebodies amongst the wider upgrade of the existing resource. The new resource estimates will be accompanied by updated exploration targets for all the orebodies on the project as well as a first exploration target for the remainder of the project area. ‘The project’s fundamentals continue to strengthen, backed by compelling economics, strong community and developmental benefits,’ company says, while ‘lithium market conditions have improved significantly, with demand outpacing supply and prices rising.’ ---------- Transense Technologies PLC - Bicester, England-based sensor technology developer - Launches new, lower-cost versions of its Translogik TLGX3 and TLGX4 tyre inspection tools, designed to make connected tyre management accessible to more fleets, OEMs, and service providers. The new models reflect Transense’s investment in product development and manufacturing efficiency, reducing cost. ---------- Altona Rare Earths PLC - Africa-focused resource exploration and development - Provides an operational update on Monte Muambe’s fluorspar resource drilling and gallium mineralogy studies. A multipurpose rig capable of both diamond drilling and reverse circulation drilling has been mobilised to site and will commence drilling shortly. Notes mineralogy characterisation results on gallium-fluorspar ore samples confirm that gallium is contained in feldspar, with grades of up to 1,700 grammes per tone, gallium. The mineralogy results confirm that during fluorspar recovery, gallium will report into the tailings, hence providing a potential two step pathway to recover both fluorspar and gallium. Advanced metallurgical studies for the production of acid-spar will also assess the recovery of gallium from fluorspar tailings. ---------- Theracryf PLC - Cheshire, England-based pharmaceutical firm focused on cancer treatment and brain disorders - Provides an update on key activity in its Ox-1 development programme. Receives notification of a Decision to Grant a Patent for its Orexin-1R antagonist in addiction from the Korean Intellectual Property Office. This grant complements TheraCryf’s broad coverage across the major commercial markets including US, EU and other Asian territories. The patent cover for this programme is composition of matter, the strongest form of patent cover available. Additionally, reports on significant development progress on the Orexin programme. The manufacturing campaign continues on-track and to-plan to produce multi kilogram quantities. An optimal formulation of the lead compound has recently been identified and, based on new data, the non-rodent species has been selected for the 28-day toxicity studies that will commence in early 2026. ---------- Copyright 2025 Alliance News Ltd. All Rights Reserved.
|
